Incidence of blast phase in myelofibrosis patients according to anemia severity at ruxolitinib start and during therapy.
Francesca PalandriGiuseppe A PalumboGiulia BenevoloAlessandra IurloElena Maria ElliElisabetta AbruzzeseNicola PolverelliMario TiribelliGiuseppe AuteriAlessia TieghiGiovanni CaocciGianni BinottoFrancesco CavazziniFilippo BranzantiEloise BeggiatoMaurizio MiglinoCostanza BosiMonica CrugnolaMonica BocchiaBruno MartinoNovella PuglieseLuigi ScaffidiMarta VenturiAndrea DuminucoAlessandro IsidoriDaniele CattaneoMauro KramperaFabrizio PaneDaniela CilloniGianpietro SemenzatoRoberto M LemoliAntonio CuneoMalgorzata M TrawinskaNicola VianelliMichele CavoMassimiliano BonifacioMassimo BrecciaPublished in: Cancer (2023)
This study highlights that anemia correlates with an increased risk of evolution into BP, both when present at baseline and when acquired during RUX monotherapy. Innovative anemia therapies and disease-modifying agents are warranted in these patients.